BioXcel Therapeutics (BTAI) Competitors $2.02 +0.05 (+2.54%) Closing price 04:00 PM EasternExtended Trading$2.08 +0.06 (+2.97%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. EYEN, ALGS, JSPR, PRLD, NBRV, PLUR, ATNM, CELU, SCLX, and KLTOShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Eyenovia (EYEN), Aligos Therapeutics (ALGS), Jasper Therapeutics (JSPR), Prelude Therapeutics (PRLD), Nabriva Therapeutics (NBRV), Pluri (PLUR), Actinium Pharmaceuticals (ATNM), Celularity (CELU), Scilex (SCLX), and Klotho Neurosciences (KLTO). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Its Competitors Eyenovia Aligos Therapeutics Jasper Therapeutics Prelude Therapeutics Nabriva Therapeutics Pluri Actinium Pharmaceuticals Celularity Scilex Klotho Neurosciences Hyperion DeFi (NASDAQ:HYPD) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability. Do institutionals and insiders hold more shares of HYPD or BTAI? 25.8% of Hyperion DeFi shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 7.1% of Hyperion DeFi shares are held by company insiders. Comparatively, 21.2% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer HYPD or BTAI? Hyperion DeFi currently has a consensus price target of $2.00, indicating a potential downside of 83.37%. BioXcel Therapeutics has a consensus price target of $42.60, indicating a potential upside of 2,008.91%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Hyperion DeFi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hyperion DeFi 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Does the media favor HYPD or BTAI? In the previous week, BioXcel Therapeutics had 2 more articles in the media than Hyperion DeFi. MarketBeat recorded 3 mentions for BioXcel Therapeutics and 1 mentions for Hyperion DeFi. BioXcel Therapeutics' average media sentiment score of 1.62 beat Hyperion DeFi's score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperion DeFi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioXcel Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is HYPD or BTAI more profitable? BioXcel Therapeutics has a net margin of -2,163.18% compared to Hyperion DeFi's net margin of -62,238.41%. Company Net Margins Return on Equity Return on Assets Hyperion DeFi-62,238.41% N/A -316.90% BioXcel Therapeutics -2,163.18%N/A -83.80% Which has better earnings & valuation, HYPD or BTAI? Hyperion DeFi has higher earnings, but lower revenue than BioXcel Therapeutics. Hyperion DeFi is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHyperion DeFi$60K577.44-$49.82M-$58.40-0.21BioXcel Therapeutics$2.27M5.39-$59.60M-$13.55-0.15 Which has more volatility and risk, HYPD or BTAI? Hyperion DeFi has a beta of 2.47, meaning that its share price is 147% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. SummaryBioXcel Therapeutics beats Hyperion DeFi on 13 of the 16 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.24M$2.95B$5.54B$9.14BDividend YieldN/A2.43%5.01%4.00%P/E Ratio-0.1521.1628.6919.46Price / Sales5.39184.72373.1779.78Price / CashN/A41.0524.7227.47Price / Book-0.077.758.255.58Net Income-$59.60M-$55.05M$3.19B$252.81M7 Day Performance6.32%12.96%5.59%3.24%1 Month Performance29.49%13.80%9.57%11.87%1 Year Performance-89.57%4.53%30.64%17.60% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics4.1605 of 5 stars$2.02+2.5%$42.60+2,008.9%-89.8%$12.24M$2.27M-0.1590Positive NewsEYENEyenoviaN/A$15.96+51.1%$2.00-87.5%N/A$45.97M$60K-0.2740Gap UpHigh Trading VolumeALGSAligos Therapeutics4.1786 of 5 stars$7.50-4.3%$70.00+833.3%-35.7%$45.83M$3.94M-0.4390JSPRJasper Therapeutics3.5633 of 5 stars$3.04-55.1%$48.00+1,478.9%-81.6%$45.66MN/A-0.5820Analyst RevisionHigh Trading VolumePRLDPrelude Therapeutics3.7269 of 5 stars$0.81+1.6%$4.50+457.8%-82.1%$45.55M$7M-0.48120Positive NewsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070PLURPluri3.4571 of 5 stars$5.79+0.2%$12.00+107.3%-7.5%$45.28M$1.03M-1.05150ATNMActinium Pharmaceuticals2.8236 of 5 stars$1.42-1.4%$4.00+181.7%N/A$44.30MN/A-1.0230Positive NewsCELUCelularity0.1022 of 5 stars$1.82-8.1%N/A-28.5%$43.59M$54.22M-0.69220Gap UpSCLXScilex2.5669 of 5 stars$6.25-1.7%$455.00+7,180.0%-90.5%$43.44M$56.59M-0.2280Positive NewsKLTOKlotho NeurosciencesN/A$1.33+16.7%N/AN/A$43.21MN/A-3.69N/AGap Down Related Companies and Tools Related Companies Eyenovia Alternatives Aligos Therapeutics Alternatives Jasper Therapeutics Alternatives Prelude Therapeutics Alternatives Nabriva Therapeutics Alternatives Pluri Alternatives Actinium Pharmaceuticals Alternatives Celularity Alternatives Scilex Alternatives Klotho Neurosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTAI Stock Alerts